Tobira Therapeutics Inc. (NASDAQ:TBRA) dropped 4.2% during trading on Monday . The stock traded as low as $4.04 and last traded at $4.13, with a volume of 257,555 shares changing hands. The stock had previously closed at $4.31.

TBRA has been the topic of several recent research reports. Cantor Fitzgerald lowered shares of Tobira Therapeutics to a “buy” rating and set a $19.00 price target on the stock. in a report on Monday, July 25th. Zacks Investment Research lowered shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Cowen and Company reaffirmed a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $18.00 price target on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $16.95.

The stock has a 50 day moving average of $10.69 and a 200-day moving average of $8.62. The stock’s market cap is $76.58 million.

Tobira Therapeutics (NASDAQ:TBRA) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. On average, equities research analysts predict that Tobira Therapeutics Inc. will post ($2.49) earnings per share for the current year.

In related news, major shareholder A/S Novo sold 187,500 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $10.37, for a total value of $1,944,375.00. Following the completion of the sale, the insider now owns 2,093,905 shares in the company, valued at $21,713,794.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the SEC. The fund purchased 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.